Skip to content
Search

Latest Stories

MHRA authorises Flublok vaccine to support vaccination programme

Community pharmacies will be able to order supplies of Flublok vaccine as the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the drug for temporary supply in the UK.

The move will make millions of extra flu jabs available to support the flu vaccination programme, billed as the largest in the UK’s history with an aim of covering over 30 million people.


“As we approach the winter and cases of Covid-19 continue to rise, it is crucial we double down on efforts to vaccinate as many people as possible from flu,” commented Professor Jonathan Van Tam, deputy chief medical officer.

“Flublok has been in regular use in the United States – and the evidence shows that it is an excellent product. I want to reassure everyone that all vaccines have undergone robust clinical trials and rigorous checks by the regulator to ensure they are safe, effective and of a high quality.”

Flublok has been used in the US since 2016 after it’s licensed by the Food and Drug Administration. A physically and biologically similar vaccine, Supemtek, has the approval of the European Medicines Agency.

“The MHRA assessed Flublok against safety, quality and effectiveness standards and sought advice from the government’s independent expert scientific advisory body - the Commission on Human Medicines. We are satisfied that this vaccine protects against flu and meets high standards of safety and quality,” said Dr Christian Schneider, interim chief scientific officer at the regulator.

Pharmacies can order stock from the government’s centrally-procured supply to complement their own flu vaccination stocks.

Free flu jabs are available to people aged 65 and over, pregnant women, and those with some pre-existing conditions; all school year groups up to year 7 and household contacts of those on the NHS Shielded Patient List.

The Department of Health and Social Care will decide on opening the programme to people aged 50 to 64 once the vaccination of these ‘at-risk’ groups is well underway.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less